Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide for diuretic-resistant oliguria in ICU patients with renal involvement
IRCT20240514061790N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, triple-blind trial of acetazolamide in oliguria and acute kidney failure (AKF) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Correction of oliguria in patients. Started Nov 2023; status: completed.
02
Drugs
acetazolamide
03
Conditions
oliguriaacute kidney failure (AKF)
Beyond the preview
Go deeper on IRCT20240514061790N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240514061790N1.